Frontiers | Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy | Oncology
Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers | Semantic Scholar
Clinical Value of Serum CEA, CA 19-9, CA 242 and AFP in Diagnosis of Gastrointestinal Tract Cancers - SciAlert Responsive Version
CA19-9 for detecting recurrence of pancreatic cancer | Scientific Reports
Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas – A retrospective tumor marker prognostic study - ScienceDirect
Positivities ofcombined tumour marker tests in patients with diseases... | Download Table
Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score - ScienceDirect
Tumor Biomarkers For Screening, Progression and Prognosis
CA 19-9 level in different T stages, grades, depth of invasion, and in... | Download Scientific Diagram
SciELO - Brasil - Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer Further evidence of the prognostic role of pretreatment levels of CA 19-9
Dynamic change of serum CA19–9 levels in benign and malignant patients with obstructive jaundice after biliary drainage and new correction formulas | BMC Cancer | Full Text
CA 19-9 as a serum marker in urothelial carcinoma Pall M, Iqbal J, Singh SK, Rana SV - Urol Ann
Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas – A retrospective tumor marker prognostic study - ScienceDirect
![PDF] Assessing Prognosis in Metastatic Pancreatic Cancer by the Serum Tumor Marker CA 19-9: Pretreatment Levels or Kinetics during Chemotherapy? | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f7bb4eb6de25f6ecb9323cbef8061896f020a0da/2-Table1-1.png "PDF] Assessing Prognosis in Metastatic Pancreatic Cancer by the Serum Tumor Marker CA 19-9: Pretreatment Levels or Kinetics during Chemotherapy? | Semantic Scholar")
PDF] Assessing Prognosis in Metastatic Pancreatic Cancer by the Serum Tumor Marker CA 19-9: Pretreatment Levels or Kinetics during Chemotherapy? | Semantic Scholar
Tumor markers in clinical practice Colorectal - CEA Hepatocellular ... | GrepMed
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine | British Journal of Cancer
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
References in How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects? - Digestive and Liver Disease
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology
Tumor Marker CA 19-9 for Assessing Pancreatic Cancer Response - Cancer Therapy Advisor
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
The Highest Ever Reported Level of Carbohydrate Antigen 19-9: A Case Report | Al-Khallaf | Journal of Medical Cases
Clinical analysis of four serum tumor markers in 458 patients with ova | CMAR
Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score - HPB
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology
CA19–9 decrease and survival according to platelet level in patients with advanced pancreatic cancer | BMC Cancer | Full Text
Comparison between CEA, CA 19-9 and CA 72-4 in Patients with Colon Cancer
